Literature DB >> 23077008

Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.

Xi Chen1, Gary K Schwartz, Lisa M DeAngelis, Thomas Kaley, Richard D Carvajal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23077008      PMCID： PMC3525312          DOI： 10.1212/WNL.0b013e318271f87e

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.

Authors:  Peter D Boasberg; Charles H Redfern; Gregory A Daniels; David Bodkin; Chris R Garrett; Alejandro D Ricart
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-24       Impact factor: 3.333

2.  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Authors:  Yevgeniy Balagula; Katherine Barth Huston; Klaus J Busam; Mario E Lacouture; Paul B Chapman; Patricia L Myskowski
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

3.  Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Authors:  John M Kirkwood; Lars Bastholt; Caroline Robert; Jeff Sosman; James Larkin; Peter Hersey; Mark Middleton; Mireille Cantarini; Victoria Zazulina; Karin Kemsley; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2011-11-02       Impact factor: 12.531

Review 4.  PET/CT imaging in inflammatory myopathies.

Authors:  Adil Al-Nahhas; Ali S M Jawad
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 5.  Exercise, MAPK, and NF-kappaB signaling in skeletal muscle.

Authors:  Henning F Kramer; Laurie J Goodyear
Journal:  J Appl Physiol (1985)       Date:  2007-02-15

6.  Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Authors:  Tammie C Yeh; Vivienne Marsh; Bryan A Bernat; Josh Ballard; Heidi Colwell; Ron J Evans; Janet Parry; Darin Smith; Barbara J Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A Lee; James D Winkler; Kevin Koch; Eli Wallace
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531
  6 in total
  9 in total

Review 1.  The clinical development of MEK inhibitors.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

2.  Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy.

Authors:  Diane Tseng; Xenos L Mason; Tomas G Neilan; Ryan J Sullivan
Journal:  Oncologist       Date:  2016-07-07

Review 3.  Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2015-09-22       Impact factor: 66.675

4.  Small molecule drugs with immunomodulatory effects in cancer.

Authors:  Adrian G Murphy; Lei Zheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.

Authors:  Alberto Vogrig; Sergio Muñiz-Castrillo; Antonio Farina; Jérôme Honnorat; Bastien Joubert
Journal:  J Neurol       Date:  2021-10-27       Impact factor: 4.849

6.  Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.

Authors:  Ping Chi; Li-Xuan Qin; Bastien Nguyen; Ciara M Kelly; Sandra P D'Angelo; Mark A Dickson; Mrinal M Gounder; Mary L Keohan; Sujana Movva; Benjamin A Nacev; Evan Rosenbaum; Katherine A Thornton; Aimee M Crago; Sam Yoon; Gary Ulaner; Randy Yeh; Moriah Martindale; Haley T Phelan; Matthew D Biniakewitz; Sarah Warda; Cindy J Lee; Michael F Berger; Nikolaus D Schultz; Samuel Singer; Sinchun Hwang; Yu Chen; Cristina R Antonescu; William D Tap
Journal:  J Clin Oncol       Date:  2022-01-18       Impact factor: 44.544

7.  Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.

Authors:  Ping Chi; Li-Xuan Qin; Niedzica Camacho; Ciara M Kelly; Sandra P D'Angelo; Mark A Dickson; Mrinal M Gounder; Mary L Keohan; Sujana Movva; Benjamin A Nacev; Evan Rosenbaum; Katherine A Thornton; Aimee M Crago; Jasmine H Francis; Moriah Martindale; Haley T Phelan; Matthew D Biniakewitz; Cindy J Lee; Samuel Singer; Sinchun Hwang; Michael F Berger; Yu Chen; Cristina R Antonescu; William D Tap
Journal:  Clin Cancer Res       Date:  2022-04-14       Impact factor: 13.801

8.  Cobimetinib-induced "dropped head syndrome" and subsequent disease management in an Erdheim-Chester patient.

Authors:  Amber C King; Eli L Diamond; Jennifer S Orozco; Hannah R Morse; Linda L Ouyang; Heiko Schöder; Raajit K Rampal
Journal:  Clin Case Rep       Date:  2019-09-10

9.  Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Authors:  Richard D Carvajal; Jeffrey A Sosman; Jorge Fernando Quevedo; Mohammed M Milhem; Anthony M Joshua; Ragini R Kudchadkar; Gerald P Linette; Thomas F Gajewski; Jose Lutzky; David H Lawson; Christopher D Lao; Patrick J Flynn; Mark R Albertini; Takami Sato; Karl Lewis; Austin Doyle; Kristin Ancell; Katherine S Panageas; Mark Bluth; Cyrus Hedvat; Joseph Erinjeri; Grazia Ambrosini; Brian Marr; David H Abramson; Mark Andrew Dickson; Jedd D Wolchok; Paul B Chapman; Gary K Schwartz
Journal:  JAMA       Date:  2014-06-18       Impact factor: 157.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.